Abstracts tagged "Renal"

Abstract Number: 0121 • ACR Convergence 2024
Intra-renal Involvement in Primary Antiphospholipid Antibodies Syndrome: Data from Two Italian Centers
Liala Moschetti¹, Savino Sciascia², Micaela Fredi³, Mattia Zappa⁴, Massimo Radin⁵, Ilaria Cavazzana³, Stefania Affatato⁶, Cecilia Nalli⁷, Laura Andreoli⁸, Federico Alberici⁹, Franco Franceschini¹, Dario Roccatello¹⁰ and Angela Tincani¹¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²University of Turin, Torino, Turin, Italy, ³Rheumatology and Clinical Immunology Unit and Department of Clinical and Experimental Sciences, ERN ReCONNET; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, ⁴Nephrology Unit and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, ⁵University of Turin, Turin, Italy, ⁶Nephrology Unit, University of Brescia, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ⁷ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁸University of Brescia, Brescia, Italy, ⁹Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, ¹⁰Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID) and Department of Clinical and Biological Sciences; San Giovanni Bosco Hospital and University of Turin, Italy, Turin, Italy, ¹¹ASST Spedali Civili-University of Brescia, Brescia, Italy
Background/Purpose: Antiphospholipid antibodies nephropathy (aPL-N) is defined by thrombotic microangiopathy (TMA) early lesions and late lesions such fibro-intimal hyperplasia with luminal obliteration/organized thrombi, fibrous arterial/arteriolar…
Abstract Number: 1521 • ACR Convergence 2024
Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
Aakash Patel¹, Baijun Zhou², Hyon K. Choi³ and April Jorge¹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…
Abstract Number: 0638 • ACR Convergence 2024
Soluble TNF RII in Lupus Nephritis as a Biomarker of Disease Activity and Treatment Response
Ranjan Gupta¹, Sonam Rajput², Jayanth Kumar² and Dipendra K Mitra², ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, New Delhi, India
Background/Purpose: Lupus Nephritis (LN) affects almost 60-70% patients of Systemic Lupus Erythematosus (SLE). Conventional markers of renal involvement i.e. proteinuria and renal biopsy have limitations…
Abstract Number: 1546 • ACR Convergence 2024
Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA
Anisha M. Patel¹, Carmen Ng¹, Lisa Lindsay¹, Zhiyu Xia², William F. Pendergraft III³ and Maria Dall'Era⁴, ¹Genentech, Inc., South San Francisco, ²Genentech, Inc., Sou, ³Genentech, Inc., Chapel Hill, NC, ⁴UCSF, Corte Madera, CA
Background/Purpose: Accounting for the integration of new immunosuppressive treatment options (belimumab and voclosporin) since 2021, we aimed to describe real-world treatment patterns in patients with…
Abstract Number: 0651 • ACR Convergence 2024
Renal Survival and Mortality in Patients with Proliferative and Membranous Lupus Nephritis
Jung-Min Shin¹, Jiyoung Lee², Hye-Soon Lee³, Sang-Cheol Bae³ and So-Young Bang³, ¹Department of Rheumatology, Nowon Eulji Medical Center, Seoul, Republic of Korea, ²Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Lupus nephritis (LN) affects approximately 50% of patients and is a major determinant in the survival and prognosis of patients with systemic lupus erythematosus…
Abstract Number: 1566 • ACR Convergence 2024
Comparative Analysis of Clinical Features and Outcomes in Late Onset vs. Early Onset Scleroderma Renal Crisis – A Multicenter Study
Sumbal Wajid¹, Lee Shapiro², Virginia Steen³, Robyn Domsic⁴, Paul J. Feustel⁵ and Swati Mehta⁶, ¹Albany Medical Center, Albany, NY, ²Division of Rheumatology, Department of Medicine, Albany Medical Center, Albany, NY, ³Georgetown University School of Medicine, Washington, DC, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁵Department of Neuroscience and Experimental Therapeutics, Albany Medical Center, Albany, NY, ⁶Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc), historically described to occur within the first 5 years of SSc diagnosis.…
Abstract Number: 0659 • ACR Convergence 2024
Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial
Richard Furie¹, Jorge A. Ross Terres², Elsa Martins³, Imran Hassan⁴, Thomas Schindler³, Jay Garg⁵, William F. Pendergraft III⁶, Ana Malvar⁷ and Brad Rovin⁸, ¹Northwell Health, Manhasset, NY, ²Genentech, Inc,, San Francisco, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁴Hoffmann-La Roche Ltd, Mississauga, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Genentech, Inc., Chapel Hill, NC, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
Abstract Number: 1569 • ACR Convergence 2024
Scleroderma Renal Crisis – Different Phenotypes and Patient Trajectories
Katya Dolnikov¹, Kochava Toledano¹, Marius Braun², Doron Markovits¹, Sami Giryes¹, Yonit Tavor¹, Alexandra Balbir-Gurman³ and Yolanda Braun Moscovici¹, ¹Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, HAIFA, Israel, ²Liver Insitute, Beilinson Hospital, Petach Tikva, Petach Tikva, Israel, ³Rheumatology Institute, Rambam Health Care Campus and The Rappaport Faculty of |Medicine, Technion, Haifa, Israel
Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication that occurs in a minority of patients, particularly those with diffuse cutaneous systemic sclerosis ( SSc).…
Abstract Number: 0701 • ACR Convergence 2024
Diagnostic Performances of Vascular Biomarkers Soluble Fms-like Tyrosine Kinase (sFlt-1) and Placental Growth Factor (PlGF) in Scleroderma Renal Crisis: A Case Control Study
Aïcha Kante¹, Paul Legendre², Bérangère Joly³, bertrand Dunogue⁴, Alexandre Hertig⁵, Benjamin Terrier⁶, Elodie Massolin⁷, Felix Ackermann⁸, Luc Mouthon⁴, Jean Guibourdenche⁹ and Benjamin Chaigne¹⁰, ¹Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, ²Service immunologie clinique, Centre hospitalier du Mans, Le Mans, France, Le Mans, ³Service d'Hématologie Biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris (APHP.Nord), Université Paris Cité, Paris, Ile-de-France, France, ⁴Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁵Department of Nephrology, Hôpital Foch, Suresnes, France, Suresnes, Ile-de-France, France, ⁶Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁷UF d'Hormonologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, Paris, Ile-de-France, France, ⁸Department of Internal Medicine, Foch Hospital, Suresnes, France., Suresnes, France, ⁹APHP-CUP, Hôpital Cochin, F-75014 Paris, Université Paris Cité, Paris, Ile-de-France, France, ¹⁰Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Scleroderma renal crisis (SRC) is a major vascular complication of systemic sclerosis (SSc), associated with high morbidity and mortality. Few biomarkers are available to predict…
Abstract Number: 1642 • ACR Convergence 2024
A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
Andrea Fava¹, Andrew Concoff², Tyler O'Malley³, Sepehr Taghavi⁴, Touba Warsi⁴, Sudha Kumar⁴, Christine Schleif⁴ and Michelle Petri⁵, ¹Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Exagen, Inc., Los Angeles, CA, ³Exagen, Vista, CA, ⁴Exagen, Carlsbad, CA, ⁵Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Achieving an NIH Activity Index of < 2 upon treatment is associated with less LN flare and thus better long-term kidney survival. Here, we…
Abstract Number: 0708 • ACR Convergence 2024
Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Vangala Adarsh¹, dihowm Fatma¹, Eyerusalem Akpan², Meredith Keller², Maheswari Muruganandam², N. Suzanne Emil², Frank O'Sullivan³, Roderick Fields² and wilmer sibbitt¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose: Use of high dose corticosteroids in systemic sclerosis (SSc) is considered a significant risk factor for development of scleroderma renal crisis (SRC). Intravenous (IV)…
Abstract Number: 1683 • ACR Convergence 2024
68Ga-FAPI PET/CT Imaging for Assessing Renal Tubulointerstitial Fibrosis in Lupus Nephritis
Shuyi Yu, Zetao Ding, Haoyu Pan, Jinyi Qian, Zhixia Yang, Xiaohan Wei, Chengde Yang and Hui Shi, Department of Rheumatology and lmmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, China (People's Republic)
Background/Purpose: To evaluate the feasibility of using fibroblast activating protein inhibitor (FAPI) PET imaging as a molecular tracer and non-invasive tool for assessing renal tubulointerstitial…
Abstract Number: 0719 • ACR Convergence 2024
Risk of Vertebral Fracture in Individuals with Granulomatosis with Polyangiitis and End-Stage Renal Disease
Joanna El Hajj¹, Jennifer Waller¹, Yagni Patel¹, Wendy Bollag¹, Stephanie Baer² and Rachel Elam³, ¹Augusta University, Augusta, GA, ²VA Augusta Healthcare System, Augusta, GA, ³Augusta University, Evans, GA
Background/Purpose: End-stage renal disease (ESRD) secondary to vasculitis is linked to a higher risk of vertebral fractures compared to other causes of ESRD. It remains…
Abstract Number: 1685 • ACR Convergence 2024
The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Achievement of Renal Responses in Lupus Nephritis
Minal Aundhia¹, Jinqi Liu², Ellen Cody³, James Rose⁴, Angela Merritt¹, Megan Quinlan-Waters¹, Alyssa Sproles⁵, Sherry Thornton⁵, Prasad Devarajan⁴, Bin Huang⁶ and hermine brunner⁷, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Bristol Myers Squibb, Princeton, NJ, ³Children's Wisconsin, Milwaukee, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Lupus Nephritis (LN) confers a poor prognosis, and there is a lack of effective non-invasive tests to assess disease activity and treatment response. We…
Abstract Number: 0725 • ACR Convergence 2024
Serum Glial Fibrillary Acidic Protein Could Assess Cross-sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Lucy Eunju Lee¹, Taejun Yoon², Yong-Beom Park² and Sang-Won Lee², ¹Yonsei University, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glial fibrillary acidic protein (GFAP), an intermediate filament protein produced by astrocytes in the CNS, has been identified as a biomarker for disease activity…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].